PriceTargets.com logo

Nkarta - NKTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $28.67
  • Forecasted Upside: 743.14%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$3.40 As of 03/30/2023 01:00 AM ET
▼ -0.11 (-3.13%)

This chart shows the closing price for NKTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nkarta Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NKTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NKTX

Analyst Price Target is $28.67
▲ +743.14% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Nkarta in the last 3 months. The average price target is $28.67, with a high forecast of $38.00 and a low forecast of $25.00. The average price target represents a 743.14% upside from the last price of $3.40.

This chart shows the closing price for NKTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 investment analysts is to buy stock in Nkarta. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/6/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/4/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/28/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/17/2023Needham & Company LLCReiterated RatingBuy$26.00Low
3/17/2023HC WainwrightReiterated RatingBuy$34.00 ➝ $30.00Low
12/22/2022OppenheimerDowngradeOutperform ➝ Market PerformLow
12/5/2022OppenheimerLower Target$36.00 ➝ $26.00Low
11/16/2022MizuhoLower TargetBuy$81.00 ➝ $26.00Low
11/10/2022OppenheimerLower TargetOutperform$50.00 ➝ $36.00Low
10/10/2022Canaccord Genuity GroupInitiated CoverageBuy$25.00Low
10/10/2022Canaccord Genuity GroupInitiated CoverageBuy$25.00Low
9/21/2022Cantor FitzgeraldReiterated RatingOverweightLow
8/12/2022Cantor FitzgeraldLower TargetOverweight$60.00 ➝ $38.00Low
7/28/2022Needham & Company LLCInitiated CoverageBuy$26.00Low
7/18/2022SVB LeerinkInitiated CoverageOutperform$30.00Low
4/26/2022Raymond JamesBoost TargetOutperform$17.00 ➝ $32.00Low
4/25/2022HC WainwrightBoost TargetBuy$25.00 ➝ $36.00High
3/29/2022Cantor FitzgeraldReiterated RatingOverweightHigh
3/11/2022Raymond JamesInitiated CoverageOutperform$17.00Medium
3/8/2022HC WainwrightInitiated CoverageBuy$25.00Low
1/6/2022William BlairInitiated CoverageOutperform$35.00High
11/18/2021Sumitomo Mitsui Financial GroupInitiated CoverageOutperform$50.00Medium
10/10/2021Evercore ISIReiterated RatingBuy$70.00Medium
7/15/2021OppenheimerInitiated CoverageOutperform$75.00Low
6/29/2021Cantor FitzgeraldBoost TargetOverweight$71.00 ➝ $78.00High
6/16/2021MizuhoReiterated RatingBuy$81.00High
5/9/2021Evercore ISIReiterated RatingBuy$70.00High
3/17/2021Cantor FitzgeraldReiterated RatingOverweightHigh
12/23/2020MizuhoBoost TargetBuy$47.00 ➝ $81.00N/A
12/7/2020MizuhoBoost TargetBuy$34.00 ➝ $47.00High
8/4/2020Evercore ISIInitiated CoverageOutperform$55.00High
8/4/2020Stifel NicolausInitiated CoverageBuy$41.00High
8/4/2020MizuhoInitiated CoverageBuy$34.00High
8/4/2020CowenInitiated CoverageOutperformHigh
(Data available from 3/30/2018 forward)

News Sentiment Rating

-0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/30/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/29/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
3/30/2023

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Nkarta logo
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Read More

Today's Range

Now: $3.40
Low: $3.32
High: $3.58

50 Day Range

MA: $4.57
Low: $3.37
High: $5.80

52 Week Range

Now: $3.40
Low: $3.28
High: $20.35

Volume

438,557 shs

Average Volume

524,418 shs

Market Capitalization

$166.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.18

Frequently Asked Questions

What sell-side analysts currently cover shares of Nkarta?

The following Wall Street research analysts have issued research reports on Nkarta in the last year: Canaccord Genuity Group Inc., Cantor Fitzgerald, HC Wainwright, Mizuho, Needham & Company LLC, Oppenheimer Holdings Inc., Raymond James, and SVB Leerink LLC.
View the latest analyst ratings for NKTX.

What is the current price target for Nkarta?

9 Wall Street analysts have set twelve-month price targets for Nkarta in the last year. Their average twelve-month price target is $28.67, suggesting a possible upside of 745.6%. Cantor Fitzgerald has the highest price target set, predicting NKTX will reach $38.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $25.00 for Nkarta in the next year.
View the latest price targets for NKTX.

What is the current consensus analyst rating for Nkarta?

Nkarta currently has 1 hold rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NKTX will outperform the market and that investors should add to their positions of Nkarta.
View the latest ratings for NKTX.

What other companies compete with Nkarta?

Other companies that are similar to Nkarta include PDS Biotechnology, Nuvectis Pharma, Aadi Bioscience, Merrimack Pharmaceuticals and Pyxis Oncology. Learn More about companies similar to Nkarta.

How do I contact Nkarta's investor relations team?

Nkarta's physical mailing address is 6000 SHORELINE COURT SUITE 102, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is 925-407-1049 and its investor relations email address is [email protected] The official website for Nkarta is www.nkartatx.com. Learn More about contacing Nkarta investor relations.